Factor VIII inhibitors demonstrate type I or type II kinetics in high‐titre alloantibodies and autoantibodies
- 1Shandong Blood Center Shandong Hemophilia Treatment Center Jinan China
- 2Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
- 3Cumming School of Medicine University of Calgary Calgary Alberta Canada
Abstract
Background In the past, most references have indicated that inhibitors in inherited haemophilia A (HA) patients had type I reaction kinetics, while inhibitors in acquired haemophilia A (AHA) had type II reaction kinetics. However, researches have also shown that samples from AHA patients exhibit type I kinetics, while inhibitor samples from HA patients may also exhibit type II kinetics. Aim To characterise inhibitor kinetics in HA patients and AHA patients in our centre. Methods Inhibitor measurement was performed using the Bethesda assay, and inhibitor type was classified by kinetic study with dilutions. The recovery of four HA patients with type II inhibitors was tested after FVIII replacement therapy. Results In the 156 HA patients with high‐titre inhibitors, 131 patients exhibited type I kinetics and 15 patients exhibited type II kinetics. In the 79 AHA patients with high‐titre inhibitors, 21 patients exhibited type I kinetics and 38 patients exhibited type II kinetics. Pharmacokinetic showed that FVIII replacement was effective in four patients with type II kinetic inhibitors. Conclusion The inhibitor kinetic type cannot be used by itself determine auto‐ versus allo‐anti‐FVIII antibody type. Inhibitors for both HA alloantibodies and AHA autoantibodies may display either type I or type II kinetics. Pharmacokinetic study suggested that patients with type II kinetics may still be treated with higher doses of FVIII replacement therapy.
Related
- Intracranial Hemorrhage in Patients Receiving Factor Xa Inhibitors: Challenges and Perspectives
- Evaluating the potential of factor XI/factor XIa inhibitors to address unmet anticoagulation needs in critical patient populations
- Systematic Review and Meta-Analysis on Central and/or Peripheral Nervous System Demyelination in Patients Treated With Tumor Necrosis Factor Alpha (TNF-α) Inhibitors
- Factors Influencing the Treatment Response of Tetracyclines for Papulopustular Rash Induced by Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Retrospective Study.
- Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review
BibTeX
@article{qiao2026factor,
title = {{Factor VIII inhibitors demonstrate type I or type II kinetics in high‐titre alloantibodies and autoantibodies}},
author = {Cuicui Qiao and Jie Wang and Tiantian Wang and Hehe Wang and Yingfang Pan and Wei Liu and Yan Cheng and Feng Xue and Man‐Chiu Poon and Xinsheng Zhang and Yunhai Fang},
journal = {Clinical and Translational Discovery},
year = {2026},
month = oct,
doi = {10.1002/ctd2.70205},
url = {https://doi.org/10.1002/ctd2.70205},
note = {CC BY},
}
RIS
TY - JOUR
TI - Factor VIII inhibitors demonstrate type I or type II kinetics in high‐titre alloantibodies and autoantibodies
AU - Cuicui Qiao
AU - Jie Wang
AU - Tiantian Wang
AU - Hehe Wang
AU - Yingfang Pan
AU - Wei Liu
AU - Yan Cheng
AU - Feng Xue
AU - Man‐Chiu Poon
AU - Xinsheng Zhang
AU - Yunhai Fang
PY - 2026
DA - 2026/10/26
JO - Clinical and Translational Discovery
DO - 10.1002/ctd2.70205
UR - https://doi.org/10.1002/ctd2.70205
AB - Background In the past, most references have indicated that inhibitors in inherited haemophilia A (HA) patients had type I reaction kinetics, while inhibitors in acquired haemophilia A (AHA) had type II reaction kinetics. However, researches have also shown that samples from AHA patients exhibit type I kinetics, while inhibitor samples from HA patients may also exhibit type II kinetics. Aim To characterise inhibitor kinetics in HA patients and AHA patients in our centre. Methods Inhibitor measurement was performed using the Bethesda assay, and inhibitor type was classified by kinetic study with dilutions. The recovery of four HA patients with type II inhibitors was tested after FVIII replacement therapy. Results In the 156 HA patients with high‐titre inhibitors, 131 patients exhibited type I kinetics and 15 patients exhibited type II kinetics. In the 79 AHA patients with high‐titre inhibitors, 21 patients exhibited type I kinetics and 38 patients exhibited type II kinetics. Pharmacokinetic showed that FVIII replacement was effective in four patients with type II kinetic inhibitors. Conclusion The inhibitor kinetic type cannot be used by itself determine auto‐ versus allo‐anti‐FVIII antibody type. Inhibitors for both HA alloantibodies and AHA autoantibodies may display either type I or type II kinetics. Pharmacokinetic study suggested that patients with type II kinetics may still be treated with higher doses of FVIII replacement therapy.
SN - 2768-0622
ER -